To create awareness about Generics treatment and make it available worldwide. My Aim is to raise awareness about hepatitis c treatment and generic. Visit here: http://anandmedicos.com/
This lecture is about Spectrum of HCV infection presented by Dr. Muhammad Mostafa Abdel Ghaffar, Head of Tropical Medicine Department, Ahmed Maher Teaching Hospital.
The lecture was presented in the scientific meeting of Internal and Tropical Medicine departments, Ahmed Maher Teaching Hospital titled (Towards Eradication of HCV in Egypt) in celebration of World Hepatitis Day on July 28, 2016.
https://www.facebook.com/AMTH.IM
https://www.facebook.com/events/1072758396145209/
http://www.no4c.com
This document provides information about Hepatitis C, including:
- Hepatitis C is a blood-borne virus that affects the liver and can lead to fibrosis and cirrhosis if left untreated.
- An estimated 300,000 Canadians are infected with Hepatitis C, many unknowingly due to a lack of symptoms.
- New direct-acting antiviral treatments have revolutionized treatment by providing pan-genotypic regimens without interferon in most cases.
- Access to treatment and support is being expanded through 17 new HCV Teams across Canada.
Christian B. Ramers, M.D., M.P.H., of Family Health Centers of San Diego, presents "The HCV Treatment Revolution: A View from the Community Health Center" for AIDS Clinical Rounds at UC San Diego
Hepatitis c. diagnosis and treatment.assld guidelines.2016 .2017Dr. Afzal Haq Asif
A 45-year-old woman presented with fatigue, weakness, loss of appetite, and anemia. Liver function tests showed elevated AST, ALT, and bilirubin levels indicating liver inflammation and damage. A liver biopsy revealed necroinflammation and fibrosis. This suggests a diagnosis of chronic hepatitis C, which would be confirmed by a positive HCV RNA test. The best course of action would be to treat the patient with direct-acting antiviral therapy to cure the hepatitis C infection, advise lifestyle changes to protect the liver, and monitor for complications like cirrhosis or liver cancer.
A 45-year-old woman presents with fatigue, weakness, loss of appetite, and abnormal liver function tests. Laboratory results show elevated AST, ALT, bilirubin levels and positive tests for HCV antibody and RNA. A liver biopsy revealed severe inflammation and bridging fibrosis. The patient is diagnosed with chronic hepatitis C virus infection based on her history of blood transfusion, symptoms, laboratory abnormalities and biopsy findings. The best course of action is to treat her HCV infection with antiviral therapy to reduce liver damage and prevent progression to cirrhosis.
The document provides information on Hepatitis C virus (HCV) including its definition, background prevalence data, transmission routes, screening and testing approaches, natural history, symptoms, treatment options, and standard precautions. It notes that HCV is a blood-borne virus that infects the liver and is transmitted through exposure to infected blood. An estimated 3% of the global population has been infected with HCV.
Hepatitis C is a major global public health problem that infects approximately 180 million people worldwide. It is a leading cause of liver disease and death, with more than 350,000-500,000 people dying each year from hepatitis C related liver disease. The virus predominantly causes chronic infection in 70-85% of cases and can lead to cirrhosis, liver failure, and hepatocellular carcinoma over time if left untreated. New direct acting antiviral regimens have revolutionized treatment and now offer cure rates over 95% with shorter, better tolerated courses of therapy.
This lecture is about Spectrum of HCV infection presented by Dr. Muhammad Mostafa Abdel Ghaffar, Head of Tropical Medicine Department, Ahmed Maher Teaching Hospital.
The lecture was presented in the scientific meeting of Internal and Tropical Medicine departments, Ahmed Maher Teaching Hospital titled (Towards Eradication of HCV in Egypt) in celebration of World Hepatitis Day on July 28, 2016.
https://www.facebook.com/AMTH.IM
https://www.facebook.com/events/1072758396145209/
http://www.no4c.com
This document provides information about Hepatitis C, including:
- Hepatitis C is a blood-borne virus that affects the liver and can lead to fibrosis and cirrhosis if left untreated.
- An estimated 300,000 Canadians are infected with Hepatitis C, many unknowingly due to a lack of symptoms.
- New direct-acting antiviral treatments have revolutionized treatment by providing pan-genotypic regimens without interferon in most cases.
- Access to treatment and support is being expanded through 17 new HCV Teams across Canada.
Christian B. Ramers, M.D., M.P.H., of Family Health Centers of San Diego, presents "The HCV Treatment Revolution: A View from the Community Health Center" for AIDS Clinical Rounds at UC San Diego
Hepatitis c. diagnosis and treatment.assld guidelines.2016 .2017Dr. Afzal Haq Asif
A 45-year-old woman presented with fatigue, weakness, loss of appetite, and anemia. Liver function tests showed elevated AST, ALT, and bilirubin levels indicating liver inflammation and damage. A liver biopsy revealed necroinflammation and fibrosis. This suggests a diagnosis of chronic hepatitis C, which would be confirmed by a positive HCV RNA test. The best course of action would be to treat the patient with direct-acting antiviral therapy to cure the hepatitis C infection, advise lifestyle changes to protect the liver, and monitor for complications like cirrhosis or liver cancer.
A 45-year-old woman presents with fatigue, weakness, loss of appetite, and abnormal liver function tests. Laboratory results show elevated AST, ALT, bilirubin levels and positive tests for HCV antibody and RNA. A liver biopsy revealed severe inflammation and bridging fibrosis. The patient is diagnosed with chronic hepatitis C virus infection based on her history of blood transfusion, symptoms, laboratory abnormalities and biopsy findings. The best course of action is to treat her HCV infection with antiviral therapy to reduce liver damage and prevent progression to cirrhosis.
The document provides information on Hepatitis C virus (HCV) including its definition, background prevalence data, transmission routes, screening and testing approaches, natural history, symptoms, treatment options, and standard precautions. It notes that HCV is a blood-borne virus that infects the liver and is transmitted through exposure to infected blood. An estimated 3% of the global population has been infected with HCV.
Hepatitis C is a major global public health problem that infects approximately 180 million people worldwide. It is a leading cause of liver disease and death, with more than 350,000-500,000 people dying each year from hepatitis C related liver disease. The virus predominantly causes chronic infection in 70-85% of cases and can lead to cirrhosis, liver failure, and hepatocellular carcinoma over time if left untreated. New direct acting antiviral regimens have revolutionized treatment and now offer cure rates over 95% with shorter, better tolerated courses of therapy.
The patient has abnormal liver enzymes and tested positive for hepatitis C virus antibodies and RNA. She has a history of injection drug use 18 years ago. Her current rash and abnormal liver enzymes suggest she may have cryoglobulinemia associated with her hepatitis C infection. Measuring her serum cryoglobulins would be the most appropriate next step to evaluate for this potential extrahepatic manifestation of hepatitis C.
This document provides information about hepatitis C virus (HCV) including its structure, genome, genotypes, epidemiology, transmission, pathogenesis, diagnosis, and management. It discusses:
- HCV has a single-stranded RNA genome within the Flaviviridae family. It exists as different genotypes that determine treatment response.
- HCV is a major cause of liver disease worldwide, with transmission primarily through blood exposure. Diagnosis involves antibody and RNA testing.
- Treatment aims to eradicate HCV and involves pegylated interferon and ribavirin combinations. Response is monitored via viral load decline. Adverse effects require monitoring and management. New direct-acting antivirals are improving treatment outcomes.
The document discusses hepatitis C, including its virology, transmission, symptoms, screening, treatment and prevention. It provides epidemiological data on chronic hepatitis C in Georgia from 2009-2014. Specifically, it finds that 50% of reported viral hepatitis cases in Georgia during this period were chronic hepatitis C. It also analyzes the age distribution and geographic distribution of chronic hepatitis C cases.
This document discusses hepatitis C virus (HCV) and current treatment options. It provides the following key points:
- HCV is the most common blood-borne pathogen in the US, with around 3.2 million people chronically infected. Chronic infections often progress to cirrhosis over 20-30 years.
- New all-oral treatment regimens that do not require interferon are highly effective. Sofosbuvir-based combinations can achieve over 90% sustained virologic response rates.
- Treatment is now recommended for most patients with chronic HCV to prevent long-term complications like cirrhosis and liver cancer. However, costs remain very high, with prices over $80,000 for a
Hepatitis C is caused by the hepatitis C virus (HCV). The document discusses HCV including its structure, replication cycle, global prevalence, genotypes found in Pakistan, natural history, extrahepatic manifestations, diagnosis, treatment options, and predictors of response to treatment. Key points are that HCV has a broad global distribution, genotype 3 is most common in Pakistan, most infections become chronic, treatment involves pegylated interferon and ribavirin, and factors like younger age and lower HCV viral load predict better response to therapy.
This document provides information about viral hepatitis, focusing on hepatitis A, B, and C. It discusses the transmission, symptoms, diagnosis, and long-term effects of each virus. Hepatitis A and B can be prevented through vaccines, while hepatitis C has no vaccine and is transmitted through blood. Over time, untreated hepatitis C can lead to cirrhosis or liver cancer, though many people have no symptoms for decades. Genotypes determine treatment options for hepatitis C.
This document provides guidelines from the WHO on chronic hepatitis C infection from April 2016. It discusses the global burden of HCV, noting over 700,000 deaths per year. New direct-acting antiviral medications have transformed HCV treatment, enabling shorter, oral regimens with over 90% cure rates and fewer side effects. The guidelines recommend screening high-risk populations and using RNA testing to confirm chronic infection before treatment. They provide guidance on clinical assessment, noting the importance of staging liver fibrosis/cirrhosis and assessing severity. Successful treatment results in reduced liver inflammation and fibrosis regression, lowering risks of liver cancer and transplant.
A 45-year-old woman presented with fatigue, weakness, loss of appetite, and slight anemia. Liver function tests showed elevated AST, ALT, and bilirubin levels. An ultrasound found a slightly decreased liver size without nodules or cirrhosis. A liver biopsy revealed inflammation and bridging fibrosis. This suggests a probable diagnosis of chronic hepatitis C infection, which can be confirmed with a HCV RNA test. The best course of action would be to start pharmacotherapy to treat the infection according to guidelines and educate the patient on prevention measures.
Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV). HCV is a spherical enveloped RNA virus that exists in 7 genotypes globally. It has structural and non-structural proteins and can cause both acute and chronic liver disease. HCV is transmitted primarily through contaminated blood and reuse of injection needles. While most infected individuals are asymptomatic, chronic infection can progress to cirrhosis or liver cancer over decades. Newer direct-acting antiviral drugs can cure over 95% of HCV infections with shorter treatment durations.
Hepatitis C is a global problem caused by the hepatitis C virus (HCV). HCV is a blood-borne virus that infects approximately 200 million people worldwide. Laboratory testing plays an important role in diagnosing HCV, evaluating patients for treatment, monitoring patients during treatment, and following up after treatment. There are 6 major genotypes of HCV with genotypes 1 and 4 being more difficult to treat and less responsive to interferon-based therapy.
This document provides information about Hepatitis C, including how it is transmitted, symptoms, diagnosis, treatment, and prevention. Some key points:
- Hepatitis C is a contagious liver disease caused by the hepatitis C virus that can range from mild to serious and lifelong.
- It is mostly transmitted through exposure to infectious blood, such as through contaminated medical equipment or injecting drug use.
- Most infected people do not show symptoms, though some may experience fatigue, abdominal pain, and jaundice. Chronic infection can lead to cirrhosis or liver cancer.
- Diagnosis involves antibody and RNA testing to confirm. People at high risk should be screened.
- Treatment involves antiviral therapy with
Hepatitis c infection, causes, treatment, and preventionNada Sami
1) Hepatitis C virus (HCV) was identified in 1989 and is a leading cause of liver disease. Egypt has the largest HCV epidemic in the world with a prevalence of 14.7% based on antibody testing.
2) HCV is a small enveloped RNA virus that is classified into 6 major genotypes. Genotypes 1 and 4 typically require longer treatment than genotypes 2, 3, 5 and 6.
3) HCV infection may be acute or chronic. About 60-70% of infections become chronic and 20% of chronic carriers may develop cirrhosis or liver cancer over time if left untreated.
The document summarizes hepatitis C (HCV), including that it is caused by the hepatitis C virus attacking the liver and leading to inflammation. Approximately 71 million people globally have chronic HCV. Acute HCV occurs within 6 months while chronic HCV lasts over 6 months, with up to 85% developing chronic disease. Symptoms range from joint/muscle issues to liver complications. Diagnosis involves blood tests to check liver enzymes and screen for HIV/HBV coinfection. Treatment has evolved so HCV is now curable, though a vaccine is still needed.
Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV): the virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.
This document discusses hepatitis B and hepatitis C, including their background, epidemiology, screening guidelines, clinical tests, and patient management. It provides an overview of each virus, explaining their transmission, disease progression, screening algorithms and tests used. The screening guidelines and phases of chronic hepatitis B are reviewed. Treatment depends on the disease phase. New diagnoses of hepatitis C are addressed, including counseling, vaccination status evaluation, lifestyle interventions and monitoring.
This document discusses hepatitis C virus (HCV) and its treatment. It begins by defining hepatitis as inflammation of the liver and describing the various causes, including viral hepatitis from hepatitis viruses A-E. It then focuses on HCV, describing it as an RNA virus that infects liver cells. The document discusses HCV transmission, signs and symptoms, natural progression to chronic infection, and treatment options to cure HCV including various antiviral medications like interferons, ribavirin, boceprevir, and sofosbuvir. It provides details on treatment regimens and success rates depending on HCV genotype.
Virus is an obligatory intracellular parasite made up of protein and RNA/DNA that replicates solely within host cells. Hepatitis C virus (HCV) is a small enveloped RNA virus that causes both acute and chronic hepatitis. It is classified into 11 genotypes and infects approximately 170 million people worldwide, with 50-80% developing chronic infection. HCV is transmitted through blood and bodily fluids, with the most common routes being contaminated needles and transfusions. While 80% of infections are asymptomatic, acute symptoms may include fatigue, nausea, and jaundice. HCV is diagnosed through antibody screening and molecular tests like PCR. Treatment aims to halt disease progression and includes antiviral drugs like interferon, ribavirin, and direct
- Hepatitis C is a contagious liver disease caused by the Hepatitis C virus. It can range from mild to severe and lifelong.
- It is commonly spread through blood-to-blood contact, especially from intravenous drug use. Other potential sources of transmission include sexual contact, transfusions, and from mother to child.
- Diagnosis involves blood tests to detect HCV antibodies and the virus. Additional tests like liver function tests and biopsy may also be used. There is no vaccine but risk of transmission can be reduced through safe practices.
Hepatitis C is a liver disease caused by the hepatitis C virus. It is transmitted through exposure to infected blood, most commonly through sharing needles or other drug use equipment. Only about one-third of people show symptoms during initial infection, which may include fatigue, abdominal pain, and jaundice. Most people go on to develop chronic hepatitis C infection without symptoms for many years. Advanced liver disease from hepatitis C may lead to complications like jaundice, ascites, bleeding, and liver cancer. Co-infection with HIV increases the challenges of diagnosing and treating hepatitis C.
Rodney Goodie leverages over two decades of experience in the health care industry to lead the St. Hope Foundation. As CEO of the Texas-based nonprofit, Rodney Goodie oversees teams that treat a broad array of conditions, including hepatitis C virus (HCV), a viral infection that can manifest after direct contact with contaminated blood. Health professionals advise patients at risk of contracting hepatitis C to undergo regular screenings.
The patient has abnormal liver enzymes and tested positive for hepatitis C virus antibodies and RNA. She has a history of injection drug use 18 years ago. Her current rash and abnormal liver enzymes suggest she may have cryoglobulinemia associated with her hepatitis C infection. Measuring her serum cryoglobulins would be the most appropriate next step to evaluate for this potential extrahepatic manifestation of hepatitis C.
This document provides information about hepatitis C virus (HCV) including its structure, genome, genotypes, epidemiology, transmission, pathogenesis, diagnosis, and management. It discusses:
- HCV has a single-stranded RNA genome within the Flaviviridae family. It exists as different genotypes that determine treatment response.
- HCV is a major cause of liver disease worldwide, with transmission primarily through blood exposure. Diagnosis involves antibody and RNA testing.
- Treatment aims to eradicate HCV and involves pegylated interferon and ribavirin combinations. Response is monitored via viral load decline. Adverse effects require monitoring and management. New direct-acting antivirals are improving treatment outcomes.
The document discusses hepatitis C, including its virology, transmission, symptoms, screening, treatment and prevention. It provides epidemiological data on chronic hepatitis C in Georgia from 2009-2014. Specifically, it finds that 50% of reported viral hepatitis cases in Georgia during this period were chronic hepatitis C. It also analyzes the age distribution and geographic distribution of chronic hepatitis C cases.
This document discusses hepatitis C virus (HCV) and current treatment options. It provides the following key points:
- HCV is the most common blood-borne pathogen in the US, with around 3.2 million people chronically infected. Chronic infections often progress to cirrhosis over 20-30 years.
- New all-oral treatment regimens that do not require interferon are highly effective. Sofosbuvir-based combinations can achieve over 90% sustained virologic response rates.
- Treatment is now recommended for most patients with chronic HCV to prevent long-term complications like cirrhosis and liver cancer. However, costs remain very high, with prices over $80,000 for a
Hepatitis C is caused by the hepatitis C virus (HCV). The document discusses HCV including its structure, replication cycle, global prevalence, genotypes found in Pakistan, natural history, extrahepatic manifestations, diagnosis, treatment options, and predictors of response to treatment. Key points are that HCV has a broad global distribution, genotype 3 is most common in Pakistan, most infections become chronic, treatment involves pegylated interferon and ribavirin, and factors like younger age and lower HCV viral load predict better response to therapy.
This document provides information about viral hepatitis, focusing on hepatitis A, B, and C. It discusses the transmission, symptoms, diagnosis, and long-term effects of each virus. Hepatitis A and B can be prevented through vaccines, while hepatitis C has no vaccine and is transmitted through blood. Over time, untreated hepatitis C can lead to cirrhosis or liver cancer, though many people have no symptoms for decades. Genotypes determine treatment options for hepatitis C.
This document provides guidelines from the WHO on chronic hepatitis C infection from April 2016. It discusses the global burden of HCV, noting over 700,000 deaths per year. New direct-acting antiviral medications have transformed HCV treatment, enabling shorter, oral regimens with over 90% cure rates and fewer side effects. The guidelines recommend screening high-risk populations and using RNA testing to confirm chronic infection before treatment. They provide guidance on clinical assessment, noting the importance of staging liver fibrosis/cirrhosis and assessing severity. Successful treatment results in reduced liver inflammation and fibrosis regression, lowering risks of liver cancer and transplant.
A 45-year-old woman presented with fatigue, weakness, loss of appetite, and slight anemia. Liver function tests showed elevated AST, ALT, and bilirubin levels. An ultrasound found a slightly decreased liver size without nodules or cirrhosis. A liver biopsy revealed inflammation and bridging fibrosis. This suggests a probable diagnosis of chronic hepatitis C infection, which can be confirmed with a HCV RNA test. The best course of action would be to start pharmacotherapy to treat the infection according to guidelines and educate the patient on prevention measures.
Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV). HCV is a spherical enveloped RNA virus that exists in 7 genotypes globally. It has structural and non-structural proteins and can cause both acute and chronic liver disease. HCV is transmitted primarily through contaminated blood and reuse of injection needles. While most infected individuals are asymptomatic, chronic infection can progress to cirrhosis or liver cancer over decades. Newer direct-acting antiviral drugs can cure over 95% of HCV infections with shorter treatment durations.
Hepatitis C is a global problem caused by the hepatitis C virus (HCV). HCV is a blood-borne virus that infects approximately 200 million people worldwide. Laboratory testing plays an important role in diagnosing HCV, evaluating patients for treatment, monitoring patients during treatment, and following up after treatment. There are 6 major genotypes of HCV with genotypes 1 and 4 being more difficult to treat and less responsive to interferon-based therapy.
This document provides information about Hepatitis C, including how it is transmitted, symptoms, diagnosis, treatment, and prevention. Some key points:
- Hepatitis C is a contagious liver disease caused by the hepatitis C virus that can range from mild to serious and lifelong.
- It is mostly transmitted through exposure to infectious blood, such as through contaminated medical equipment or injecting drug use.
- Most infected people do not show symptoms, though some may experience fatigue, abdominal pain, and jaundice. Chronic infection can lead to cirrhosis or liver cancer.
- Diagnosis involves antibody and RNA testing to confirm. People at high risk should be screened.
- Treatment involves antiviral therapy with
Hepatitis c infection, causes, treatment, and preventionNada Sami
1) Hepatitis C virus (HCV) was identified in 1989 and is a leading cause of liver disease. Egypt has the largest HCV epidemic in the world with a prevalence of 14.7% based on antibody testing.
2) HCV is a small enveloped RNA virus that is classified into 6 major genotypes. Genotypes 1 and 4 typically require longer treatment than genotypes 2, 3, 5 and 6.
3) HCV infection may be acute or chronic. About 60-70% of infections become chronic and 20% of chronic carriers may develop cirrhosis or liver cancer over time if left untreated.
The document summarizes hepatitis C (HCV), including that it is caused by the hepatitis C virus attacking the liver and leading to inflammation. Approximately 71 million people globally have chronic HCV. Acute HCV occurs within 6 months while chronic HCV lasts over 6 months, with up to 85% developing chronic disease. Symptoms range from joint/muscle issues to liver complications. Diagnosis involves blood tests to check liver enzymes and screen for HIV/HBV coinfection. Treatment has evolved so HCV is now curable, though a vaccine is still needed.
Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV): the virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.
This document discusses hepatitis B and hepatitis C, including their background, epidemiology, screening guidelines, clinical tests, and patient management. It provides an overview of each virus, explaining their transmission, disease progression, screening algorithms and tests used. The screening guidelines and phases of chronic hepatitis B are reviewed. Treatment depends on the disease phase. New diagnoses of hepatitis C are addressed, including counseling, vaccination status evaluation, lifestyle interventions and monitoring.
This document discusses hepatitis C virus (HCV) and its treatment. It begins by defining hepatitis as inflammation of the liver and describing the various causes, including viral hepatitis from hepatitis viruses A-E. It then focuses on HCV, describing it as an RNA virus that infects liver cells. The document discusses HCV transmission, signs and symptoms, natural progression to chronic infection, and treatment options to cure HCV including various antiviral medications like interferons, ribavirin, boceprevir, and sofosbuvir. It provides details on treatment regimens and success rates depending on HCV genotype.
Virus is an obligatory intracellular parasite made up of protein and RNA/DNA that replicates solely within host cells. Hepatitis C virus (HCV) is a small enveloped RNA virus that causes both acute and chronic hepatitis. It is classified into 11 genotypes and infects approximately 170 million people worldwide, with 50-80% developing chronic infection. HCV is transmitted through blood and bodily fluids, with the most common routes being contaminated needles and transfusions. While 80% of infections are asymptomatic, acute symptoms may include fatigue, nausea, and jaundice. HCV is diagnosed through antibody screening and molecular tests like PCR. Treatment aims to halt disease progression and includes antiviral drugs like interferon, ribavirin, and direct
- Hepatitis C is a contagious liver disease caused by the Hepatitis C virus. It can range from mild to severe and lifelong.
- It is commonly spread through blood-to-blood contact, especially from intravenous drug use. Other potential sources of transmission include sexual contact, transfusions, and from mother to child.
- Diagnosis involves blood tests to detect HCV antibodies and the virus. Additional tests like liver function tests and biopsy may also be used. There is no vaccine but risk of transmission can be reduced through safe practices.
Hepatitis C is a liver disease caused by the hepatitis C virus. It is transmitted through exposure to infected blood, most commonly through sharing needles or other drug use equipment. Only about one-third of people show symptoms during initial infection, which may include fatigue, abdominal pain, and jaundice. Most people go on to develop chronic hepatitis C infection without symptoms for many years. Advanced liver disease from hepatitis C may lead to complications like jaundice, ascites, bleeding, and liver cancer. Co-infection with HIV increases the challenges of diagnosing and treating hepatitis C.
Rodney Goodie leverages over two decades of experience in the health care industry to lead the St. Hope Foundation. As CEO of the Texas-based nonprofit, Rodney Goodie oversees teams that treat a broad array of conditions, including hepatitis C virus (HCV), a viral infection that can manifest after direct contact with contaminated blood. Health professionals advise patients at risk of contracting hepatitis C to undergo regular screenings.
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. HCV is spread through contact with infected blood, such as through intravenous drug use, unsafe medical procedures, and sexual or household contact with an infected person. Most people infected with HCV develop chronic hepatitis C, where the virus remains in the body, often for life. Chronic hepatitis C can cause serious damage to the liver, leading to complications like cirrhosis or liver cancer. While there is no vaccine, hepatitis C can be cured through antiviral treatment. Prevention focuses on avoiding contact with infected blood and getting tested if engaging in risky behaviors.
Epidemiologic characteristics of Hemocontact Infections. Viral hepatitis B. V...Aniuta Sydorchuk
This document discusses hemocontact infections, which are blood-borne infections transmitted via contact with blood or other body fluids. It focuses on viral hepatitis B, viral hepatitis C, and Ebola hemorrhagic fever. For each disease, it covers the etiology, epidemiology, pathogenesis, clinical presentation, diagnosis, treatment and prevention. It compares the key differences between hepatitis B and C, such as transmission routes, incubation periods, likelihood of chronic infection, and serological tests used for diagnosis. For Ebola, it describes the disease progression, symptoms, laboratory diagnostics and supportive care approach, as there are currently no approved vaccines or treatments.
"Get effective Hepatitis C treatment at Kaizen Gastro Care in Pune. Our expert team provides comprehensive care and advanced therapies for Hepatitis C. Regain your health with personalized treatment plans. Book a consultation today.
"
A 47-year-old woman presented with fever, cough, and difficulty breathing for one week. She was diagnosed with HIV 5 years ago but stopped treatment after one month. She now has oral thrush, tachycardia, and crackles in her lungs. Her CD4 count is low at 235 and HIV viral load is high. She is diagnosed with Pneumocystis jiroveci pneumonia, an opportunistic infection seen in advanced HIV/AIDS due to her severely compromised immune system from lack of antiretroviral treatment.
HEPATITIS_B_presentation disease control and management.pptnikhilgendre1
Hepatitis B is a viral infection that causes inflammation of the liver. It is spread through contact with infected blood or bodily fluids. The virus can cause both acute and chronic infections. Acute infections may cause symptoms but often resolve on their own, while chronic infections can lead to long-term liver damage. Hepatitis B can be prevented through vaccination. Those at high risk should be screened and infected individuals can be treated to reduce the risk of cirrhosis and liver cancer.
Hep C Connection Presentation for 9Health Fair Site Leadershcvoutreach
Hep C Connection is partnering with 9Health Fair to provide hepatitis C antibody screening at several sites in spring 2015. They will assist with education and testing sign-up. Anyone born between 1945-1965 should get a one-time hepatitis C screening, as baby boomers account for most chronic cases in the US. Most people infected have no symptoms, so testing is important even with just one risk factor like past injection drug use. A positive antibody test requires a follow up viral load test to confirm infection status.
Hepatitis is inflammation of the liver that can be caused by viruses, alcohol, obesity, or the immune system. The major types of viral hepatitis are hepatitis A, B, C, D, and E, which are spread through food, water, blood or sexual contact. Hepatitis B and C often become chronic infections and can lead to cirrhosis or liver cancer if not treated. While hepatitis A and E usually only cause acute infections, hepatitis B, C and D pose longer term risks. Lifestyle changes and vaccines can help prevent hepatitis in many cases.
Hepatitis means inflammation of the liver. The liver is a vital organ that processes nutrients, filters the blood, and fights infections. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can cause hepatitis.
The role that a dentist can play in prevention of hepatitis is by considering each and every patient as a potential carrier of hepatitis. Proper infection control and sterilization protocols should be followed in order to reduce the risk of infection. Dental surgeons are at a greater risk of exposure than the other specialists in the medical fields because of their exposure to aerosols during ultrasonic scaling. So, they should lay special emphasis on prevention and protection against hepatitis.
Merely celebrating World Hepatitis Day on 28 July is not sufficient for increasing awareness in the community. It is an opportunity for the people and health policy makers globally for more knowledge sharing and finding better approaches for control of HBV and HCV infections in their communities. The role of media in collaboration with gastroenterologists, hepatologists, general and dental surgeons, and infectious centers for generation of massive public informative and educational materials is very critical.
The following are the guidelines for treating hepatitis patients
No dental treatment other than urgent care should be rendered for a patient with acute viral hepatitis[2]
Hepatitis B is of primary concern to the dentist. Individuals still carry the virus up to 3 months after the symptoms have disappeared, so any patient with a recent history of hepatitis B should be treated for dental emergency problems only[6]
For patient with a past history of hepatitis, consult the physician to determine the type of hepatitis, course and length of the disease, mode of transmission, and any chronic liver disease or viral carrier state
For recovered HAV or HEV, perform routine periodontal care
For recovered HBV and HDV, consult with the physician and order HBsAg and HBs laboratory tests.
If HBsAg and anti-HBs tests are negative but HBV is suspected, order another HBs determination
Patients who are HBsAg positive are probably infective (chronic carriers); the degree of infectivity is measured by an HBsAg determination
Patients who are anti-HBs positive may be treated routinely
Patients who are HBsAg negative may be treated routinely..
Work practice controls are an important adjunct for preventing blood exposures. They are as follows:[23]
Using a one-handed scoop technique, a mechanical device designed for holding the needle cap to facilitate one-handed recapping, or an engineered sharp injury protection device (e.g., needles with re-sheathing mechanisms) for recapping needles between uses and before disposal
Not bending or breaking needles before disposal
Avoid passing a syringe with an unsheathed needle.
Hepatitis C is a contagious liver disease that can range from mild illness to serious lifelong illness or death. It is caused by the hepatitis C virus (HCV) and is most commonly spread through blood-to-blood contact. While there is no vaccine, current treatment involves pegylated interferon and ribavirin. This therapy cures hepatitis C if it results in a sustained virologic response (SVR), meaning the virus is undetectable 6 months after treatment ends. SVR rates are lower for HCV genotype 1 than other genotypes. Newer treatments are being developed to make therapy easier and more effective. Tailoring treatment based on factors like early viral load response may allow some genotype 1 patients to
HIV Nursing and Home & Community Care Conference griehl
This joint presentation by Susann Nasewich and Greg Riehl will describe HIV Nursing as it relates to pre and post test counseling, and what is important to know for home and community care nurses and aides.
Hepatitis C is a disease that affects the liver and is caused by the hepatitis C virus (HCV). Approximately 3.2 million people in the United States are thought to have chronic hepatitis C. The virus replicates in the liver and triggers an immune response that can lead to liver scarring and loss of function over many years. Most people develop a chronic HCV infection, though some clear the virus early on. Hepatitis C is diagnosed through antibody and RNA tests to detect the virus. There is no vaccine and many people are unaware they are infected.
Hepatitis C is a disease that affects the liver and is caused by the hepatitis C virus (HCV). Approximately 3.2 million people in the United States are thought to have chronic hepatitis C. The virus replicates in the liver and triggers an immune response that can lead to liver scarring and loss of function over many years. Most people develop a chronic HCV infection, though some clear the virus early on. Hepatitis C is diagnosed through antibody and RNA tests to detect the virus. There is no vaccine and many people are unaware they are infected.
Hepatitis C is a disease that affects the liver caused by the hepatitis C virus (HCV). Approximately 3.2 million people in the US have chronic hepatitis C. The virus replicates in the liver and triggers an immune response that can cause scarring and loss of liver function over many years. Most people develop a chronic HCV infection. Hepatitis C is diagnosed through an antibody test to detect past infection and an RNA test to detect the current presence of the virus. There is no vaccine and many people are unaware they are infected.
Explore our comprehensive Hepatitis C PowerPoint presentation (PPT) to gain in-depth knowledge of this liver-related viral infection. This expertly crafted presentation covers the causes, symptoms, diagnosis, and treatment options for Hepatitis C. Ideal for medical professionals and the general public, it provides a holistic understanding of the disease, its transmission, risk factors, symptoms, diagnostic procedures, and the latest treatment advancements. Additionally, learn about prevention measures, lifestyle recommendations, and stay up-to-date with current research in the field. Our visually engaging PPT combines informative content with images, diagrams, and charts, making it an accessible resource for medical students, healthcare practitioners, and those seeking knowledge about Hepatitis C. Get a comprehensive insight into Hepatitis C with our educational presentation.
This document provides information on HIV/AIDS including its epidemiology, transmission, stages, diagnosis, treatment and prevention. It describes HIV/AIDS as a global public health issue and outlines prevention strategies like safe sex practices, antiretroviral treatment, prevention of mother-to-child transmission and harm reduction for intravenous drug users. Statistics on HIV prevalence in Pakistan are presented alongside the national AIDS control program and its strategies to promote awareness, testing and care.
This document discusses hepatitis C, D, and E. It defines each type of hepatitis, describing how they are transmitted and their risk factors. Hepatitis causes liver inflammation and can be acute or chronic. Hepatitis C is caused by the hepatitis C virus and spreads through blood exposure, while hepatitis D only infects those also infected with hepatitis B. Hepatitis E spreads through contaminated food or water and is common in developing countries with poor sanitation. The document outlines the clinical manifestations, diagnostic tests, management, and prevention of hepatitis C, D, and E.
Similar to Hepatitis C Infection Anand Medicos (20)
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. WHAT IS HEPATITIS?
• “Hepatitis” means inflammation of the liver
• Can be caused by:
• Genetic diseases
• Medications (including over-the-counter)
• Alcohol
• Hepatitis viruses (A,B,C,D,E)
anandmedicos.com
3. HEPATITIS C
▪ Identified in 1989
▪ Blood test became available in 1992
▪ Used to be known as “non-A, non-B”
hepatitis
▪ Spread through blood-to- blood contact
▪ No vaccine available to prevent
hepatitis C
anandmedicos.com
5. HEPATITIS C - A GLOBAL INFECTION
• About 3 million Americans infected
• About 170 million infected worldwide
• Many do not experience symptoms
anandmedicos.com
6. SOURCES OF INFECTION FOR PERSONS WITH
HEPATITIS C
Sexual 15%
Other* 5%
Unknown 10%
Injecting drug use 60%
Transfusion 10%
(before screening)
anandmedicos.com
7. • Hepatitis C is a contagious liver disease
that results from infection with the
Hepatitis C virus. It can range in severity
from a mild illness lasting a few weeks to
a serious, lifelong illness. Hepatitis C is
usually spread when blood from a person
infected with the Hepatitis C virus enters
the body of someone who is not infected
WHAT IS HEPATITIS C
INFECTION
anandmedicos.com
8. HEPATITIS C - EPIDEMIOLOGY
Before 1985 1999
Illegal Drug Use
Transfusion
Sexual
Other
Unknown
anandmedicos.com
11. WHAT HAPPENS TO PEOPLE WITH
HEPATITIS C VIRUS?
anandmedicos.com
Infected With Hepatitis C
100
15
No Chronic Disease
Chronic Disease
85
Cirrhosis
17
2
Liver Cancer
12. CHRONIC HEPATITIS C
FACTORS PROMOTING PROGRESSION OR SEVERITY
• Increased alcohol intake
• Age > 40 years at time of infection
• HIV co-infection ? Other
• Male gender
• Other co-infections (e.g., HBV)
anandmedicos.com
13. ALCOHOL MAJOR CONTRIBUTOR FOR PROGRESS
OF DISEASE
Drinker Without Hepatitis C
Drinker With Hepatitis C
Hepatitis C Non-Drinker
Chance Of Getting
Cirrhosis
Non-Drinker
anandmedicos.com
14. HEPATITIS C CAN PRESENT AS ACUTE OR
CHRONIC INFECTION
• Hepatitis C can be either “acute” or
“chronic.” Acute Hepatitis C virus infection
is a short-term illness that occurs within
the first 6 months after someone is
exposed to the Hepatitis C virus. For most
people, acute infection leads to chronic
infection. Chronic Hepatitis C is a serious
disease than can result in long-term health
problems, or even death.
anandmedicos.com
15. TRANSMISSION / EXPOSURE
• Hepatitis C is spread when blood from a person infected with the Hepatitis C
virus enters the body of someone who is not infected. Today, most people
become infected with the Hepatitis C virus by sharing needles or other
equipment to inject drugs. Before 1992, when widespread screening of the blood
supply began in the United States, Hepatitis C was also commonly spread
through blood transfusions and organ transplants.
• People can become infected with the Hepatitis C virus during such activities as
Sharing needles, syringes, or other equipment to inject drugs Needle stick
injuries in health care settings
• Being born to a mother who has Hepatitis C
anandmedicos.com
16. LESS COMMONLY TRANSMITTED THROUGH …
• Less commonly, a person can also
get Hepatitis C virus infection
through Sharing personal care items
that may have come in contact with
another person’s blood, such as
razors or toothbrushes
• Having sexual contact with a person
infected with the Hepatitis C virus
anandmedicos.com
17. WHO SHOULD BE TESTED FOR HEPATITIS C ?
▪ People with risk factors for hepatitis C
▪ Those who wish to be tested
anandmedicos.com
18. • You are a current or former injection drug user, even if you injected
only one time or many years ago.
• You were treated for a blood clotting problem before 1987.
• You received a blood transfusion or organ transplant before July 1992.
• You are on long-term hemodialysis treatment.
• You have abnormal liver tests or liver disease.
• You work in health care or public safety and were exposed to blood
through a needle stick or other sharp object injury.
• You are infected with HIV.
WHO SHOULD BE TESTED FOR HEPATITIS C ?
anandmedicos.com
19. HCV TESTING ROUTINELY RECOMMENDED
Based on increased risk for infection
• Ever injected illegal drugs
• Received clotting factors made before 1987
• Received blood/organs before July 1992
• Ever on chronic hemodialysis
• Evidence of liver disease
• Healthcare, emergency, public safety workers after needle
stick/mucosal exposures to HCV-positive blood
• Children born to HCV-positive women
anandmedicos.com
20. ROUTINE HCV TESTING NOT RECOMMENDED
(UNLESS RISK FACTOR IDENTIFIED)
• Health-care, emergency medical,
and public safety workers
• Pregnant women
• Household (non-sexual) contacts of
HCV-positive persons
• General population
anandmedicos.com
21. HCV INFECTION TESTING ALGORITHM
FOR DIAGNOSIS OF ASYMPTOMATIC PERSONS
EIA for Anti-HCV
Negative
(non-reactive)
STOP
Positive (repeat reactive)
OR
RIBA for Anti-HCV RT-PCR for HCV RNA
Negative
STOP
Additional Laboratory
Evaluation (e.g. PCR, ALT)
Negative PositiveIndeterminate
Medical
Evaluation
Positive
Negative PCR,
Normal ALT
Positive PCR,
Abnormal ALT
anandmedicos.com
22. HOW IS HEPATITIS C DIAGNOSED?
• Blood testing
1. Hepatitis C antibody test
2. Hepatitis C PCR test to find
virus in blood
• Liver function tests
anandmedicos.com
23. LABORATORY DIAGNOSIS
• Serologic tests to detect HCV antibodies:
- enzyme immunoassay (EIA). False negative in pts on HD,
immunodeficiency; false positive in autoimmune disorder.
- recombinant immunoblot assay (RIBA)
• Target amplification technique to detect HCV RNA (molecular assay)
- polymerase chain reaction (PCR). A positive test confirms HCV
infection.
anandmedicos.com
24. CURRENTLY PERFORMED TESTES FOR
HEPATITIS C INFECTION
• Currently, the second-generation enzyme
immunoassay (EIA-2) for antibodies to HCV
(anti-HCV) is the most practical screening test
for HCV infection. The diagnosis of HCV
infection can be supported or confirmed by the
recombinant immunoblots assay (RIBA) or
tests for HCV RNA. RIBA detects antibodies to
individual HCV antigens and confers
increased specificity compared to EIA-2.
anandmedicos.com
25. MOLECULAR METHODS IN DIAGNOSIS OF
HEPATITIS C INFECTION
• Qualitative reverse transcription-
polymerase chain reaction (RT-PCR)
assays for HCV RNA are simpler
than quantitative tests and sufficient
for confirmation of the diagnosis of
HCV infection.
anandmedicos.com
26. ALANINE AMINOTRANSFERASE
• Serum ALT testing is inexpensive and noninvasive.
• Insensitive means of monitoring disease activity.
• A single determination gives limited information, and serial measurements
recommended.
• Weak association between the degree of ALT elevation and severity of
histopathological findings on liver biopsy.
• Resolution of ALT elevation with antiviral therapy appears to indicate
disease response.
27. Serologic Pattern of Acute HCV Infection
with Recovery
Symptoms +/-
Time after Exposure
Titer
anti-HCV
ALT
Normal
0 1 2 3 4 5 6 1 2 3 4
YearsMonths
HCV RNA
anandmedicos.com
28. Serologic Pattern of Acute HCV Infection with
Progression to Chronic Infection
Symptoms +/-
Time after Exposure
Titer
anti-HCV
ALT
Normal
0 1 2 3 4 5 6 1 2 3 4
YearsMonths
HCV RNA
anandmedicos.com
29. LIVER BIOPSY
• Provides useful information about the degree
of fibrosis in HCV infected patients. This
information is important in management
decisions.
• Is not used for diagnosis of HCV infection.
• Used for assessment of severity of
inflammation, presence of fibrosis, evaluate
possible concomitant disease processes,
assess therapeutic intervention.
anandmedicos.com
30. LIVER HISTOLOGY
• Activity (necro-inflammation) – severity and
progress. May fluctuate with disease
activity or therapeutic intervention.
• Fibrosis implies possible progression to
cirrhosis. In mild cases, is limited to portal
and periportal area. More advanced
changes defined by ‘bridging fibrosis’.
• Cirrhosis
anandmedicos.com
31. DIAGNOSTIC ASSESSMENT OF INFECTED PATIENTS
• In summary, the diagnostic algorithm of
Hepatitis C depends on the clinical
context. In asymptomatic, low-risk
subjects, who are found to be anti-HCV-
positive by EIA-2, the diagnosis of HCV
infection needs to be confirmed,
especially if the initial biochemical tests
reveal normal ALT levels.
anandmedicos.com
32. CAN WE PREVENT HEPATITIS C INFECTION
• There is no vaccine for Hepatitis C.
The best way to prevent Hepatitis C
is by avoiding behaviors that can
spread the disease, especially
injection drug use.
anandmedicos.com
Many things can cause hepatitis.
With hepatitis C you need to be careful not to do anything that will irritate your liver
With hepatitis the liver enzymes are usually elevated and the liver can become enlarged
Important to stress the fact that HCV does not always have symptoms. Can feel healthy for 10-20 or more years before developing symptoms. Patient can be asymptomatic but have hepatitis C.
Symptoms are often very mild, but liver damage can occur without symptoms.
No vaccine is available for hepatitis C, but researchers are working hard. The virus mutates quickly making it difficult to make a vaccine.
4 times more common than HIV
Fewer people are transmitting HCV now compared to 20-30 years ago.
About 30,000 more become infected each year
Hepatitis C infection has major epidemic implications due to the natural history of the infection. Unlike Hepatitis B infections, where a small proportion of cases go on to chronic infection and thus, infectious states, the majority of Hepatitis C infections progress to chronic states. HCV viral loads do not correlate well with disease progression in the liver, however. Of those chronically infected, progression to liver disease (fibrosis) usually occurs in about 10 years, with progression to cirrhosis after about 20 years (hepatocellular carcinoma generally develops in a small percentage after about 30 years).
REFERNCES
Seeff LB. “Natural history of hepatitis C.” American Journal of Medicine 1999; 107(6B): 10S-15S.
Tong MJ, El-Farra NS, Reikes AR, Co RL. “Clinical outcomes after transfusion-associated hepatitis C.” New England Journal of Medicine 1995; 332: 1463-1466.
Chronic disease means that the person will carry the virus in their blood long-term.
No chronic disease means that the person will not carry the virus in their blood long-term, but will still have the antibodies in their blood.
To read the above graph in black and white:
The first bullet ‘non-drinker’ corresponds to the smallest circle. As you go down the list of bullets the circles get bigger with ‘hepatitis C drinker’ being the largest circle.
Alcohol is a direct poison to your liver. It prevents your body from absorbing certain vitamins that it needs to work properly. It can also make your hepatitis C medicine less effective. Alcohol damages your liver even when you are healthy. Drinking alcohol when you have hepatitis C make the damage much worse.
14. Department of Veteran Affairs, Hepatitis C Brochure Series, If You Have Hepatitis C Infection, http://www.va.gov/hepatitisC
What about alcohol? How much is bad? 1-3 ounces? I’ve heard that a small amount of alcohol is good for you.
At this time, we’re not sure.
Is it okay to drink non-alcoholic wines?
It’s not suggested.
In the future when I clear the HCV can I drink alcohol?
It depends on the amount of scarring in your liver.
For more information refer to reference 15 at the end of the slide set